T

he Trump administration may hand the pharmaceutical industry a gift, at least temporarily.

A controversial rule that would penalize drug makers for overcharging hospitals, clinics, and other providers for medicines that are purchased under the federal government’s 340B drug discount program may be delayed by nearly an entire year.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X